| Christine A Hamilton, CRNA | |
|
1501 E 3rd St, Delta, CO 81416-2815 | |
| (970) 874-7681 | |
| Not Available |
| Full Name | Christine A Hamilton |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 23 Years |
| Location | 1501 E 3rd St, Delta, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326144338 | NPI | - | NPPES |
| HA800403 | Other | CO | BCBS |
| 76406521 | Medicaid | CO | |
| 840428757028 | Other | CO | ROCKY MOUNTAIN HEALTH PLA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 109969 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Delta County Memorial Hospital | Delta, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Delta County Memorial Hospital | 1850200601 | 59 |
News Archive
As President Barack Obama and House Speaker John Boehner continue trying to move toward an ambitious $4 trillion grand bargain, reports indicate that wide differences remain. Still in the mix are cuts to Medicare, Medicaid and other government programs that would be combined with revenue increases resulting from a tax code revamp.
Results of a new study suggest that three new diagnostic tests could each be used to successfully diagnose drug resistance in tuberculosis (TB) patients in a quarter of the time taken by the current method.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.
› Verified 4 days ago
| Entity Name | Delta County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417935446 PECOS PAC ID: 1850200601 Enrollment ID: O20040113000653 |
News Archive
As President Barack Obama and House Speaker John Boehner continue trying to move toward an ambitious $4 trillion grand bargain, reports indicate that wide differences remain. Still in the mix are cuts to Medicare, Medicaid and other government programs that would be combined with revenue increases resulting from a tax code revamp.
Results of a new study suggest that three new diagnostic tests could each be used to successfully diagnose drug resistance in tuberculosis (TB) patients in a quarter of the time taken by the current method.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.
› Verified 4 days ago
| Entity Name | Ecgj Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609120070 PECOS PAC ID: 9133364466 Enrollment ID: O20130314000349 |
News Archive
As President Barack Obama and House Speaker John Boehner continue trying to move toward an ambitious $4 trillion grand bargain, reports indicate that wide differences remain. Still in the mix are cuts to Medicare, Medicaid and other government programs that would be combined with revenue increases resulting from a tax code revamp.
Results of a new study suggest that three new diagnostic tests could each be used to successfully diagnose drug resistance in tuberculosis (TB) patients in a quarter of the time taken by the current method.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.
› Verified 4 days ago
| Entity Name | Grand Mesa Spine And Sport Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700220993 PECOS PAC ID: 0648408625 Enrollment ID: O20140121001099 |
News Archive
As President Barack Obama and House Speaker John Boehner continue trying to move toward an ambitious $4 trillion grand bargain, reports indicate that wide differences remain. Still in the mix are cuts to Medicare, Medicaid and other government programs that would be combined with revenue increases resulting from a tax code revamp.
Results of a new study suggest that three new diagnostic tests could each be used to successfully diagnose drug resistance in tuberculosis (TB) patients in a quarter of the time taken by the current method.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.
› Verified 4 days ago
| Entity Name | Amel Med, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356894059 PECOS PAC ID: 9537455845 Enrollment ID: O20160913002729 |
News Archive
As President Barack Obama and House Speaker John Boehner continue trying to move toward an ambitious $4 trillion grand bargain, reports indicate that wide differences remain. Still in the mix are cuts to Medicare, Medicaid and other government programs that would be combined with revenue increases resulting from a tax code revamp.
Results of a new study suggest that three new diagnostic tests could each be used to successfully diagnose drug resistance in tuberculosis (TB) patients in a quarter of the time taken by the current method.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.
› Verified 4 days ago
| Entity Name | Arlington Anesthesia Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023483153 PECOS PAC ID: 2860798303 Enrollment ID: O20170823002989 |
News Archive
As President Barack Obama and House Speaker John Boehner continue trying to move toward an ambitious $4 trillion grand bargain, reports indicate that wide differences remain. Still in the mix are cuts to Medicare, Medicaid and other government programs that would be combined with revenue increases resulting from a tax code revamp.
Results of a new study suggest that three new diagnostic tests could each be used to successfully diagnose drug resistance in tuberculosis (TB) patients in a quarter of the time taken by the current method.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christine A Hamilton, CRNA Po Box 10100, Delta, CO 81416-0008 Ph: (970) 874-2470 | Christine A Hamilton, CRNA 1501 E 3rd St, Delta, CO 81416-2815 Ph: (970) 874-7681 |
News Archive
As President Barack Obama and House Speaker John Boehner continue trying to move toward an ambitious $4 trillion grand bargain, reports indicate that wide differences remain. Still in the mix are cuts to Medicare, Medicaid and other government programs that would be combined with revenue increases resulting from a tax code revamp.
Results of a new study suggest that three new diagnostic tests could each be used to successfully diagnose drug resistance in tuberculosis (TB) patients in a quarter of the time taken by the current method.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.
› Verified 4 days ago
Mr. Carey B Simon, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 E 3rd St, Delta, CO 81416 Phone: 970-874-2255 | |
Clint B Pitchforth, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 E 3rd St, Delta, CO 81416 Phone: 970-874-7681 Fax: 970-874-6400 | |
Joseph Duane Mcbeain, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 236 Cottonwood St, Delta, CO 81416 Phone: 970-546-4010 Fax: 970-546-4016 | |
Kimberley W Brighton, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1501 E 3rd St, Delta, CO 81416 Phone: 970-874-7681 | |
Kathy R Akers, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 E 3rd St, Delta, CO 81416 Phone: 970-874-7681 | |
Joshua Lake, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 E 3rd St, Delta, CO 81416 Phone: 970-874-7681 |